Research & Innovation Section · April 2026
- 3 hours ago
- 3 min read
A new perspective to improve the daily lives of patients suffering from endometriosis
Written by Dr. Adrien Crestani, Instructor – IFEM Endo Academy & Surgeon in complex endometriosis care
Managing pain, anxiety, fatigue, sexuality, diet… Endometriosis requires global, multidisciplinary care, and yet, most patients do not have access to it. What if a mobile application, prescribed by a doctor, could change the game? This is precisely the question posed by the LYVENDO study, in which IFEM Endo Bordeaux is participating.
A complex pathology in search of new solutions
A chronic and multifactorial disease, it has to this day no curative treatment. Scientific data have supported for several years an integrative approach associating therapeutic education, adapted physical activity, psychological support, and dietary accompaniment, in coherence with the recommendations of the Haute Autorité de Santé (HAS) on the management of chronic pain. But in practice, access to this type of multidisciplinary follow-up remains poorly accessible: specialists are few and the integrative approach remains still little known by front-line professionals.
A promising digital solution
Developed by Lyv Healthcare, Lyv Endo® is a class I medical device, CE marked and ISO 13485 certified. It offers patients suffering from endometriosis a personalized therapeutic program, structured around five pillars: knowledge of the disease, mental well-being, adapted physical activity, diet, and sexual health. The content is dynamically adapted to the symptoms declared by the patient, with an objective of establishing new habits over three months.
An observational pilot study on a similar application showed a difference of 7.4/100 points on the EHP-30 score between users and non-users after two weeks. Preliminary data from an internal pilot study evaluating a similar program showed a difference of approximately 6 points on the EHP-5 score between the two groups after three months, suggesting a clinically significant impact on the quality of life. The LYVENDO study (NCT07175857) aims to confirm this result under real-world practice conditions, within the framework of a randomized controlled trial with the participation of IFEM Endo Bordeaux as one of the main clinical sites.
Study Design
The controlled, randomized, and multicenter clinical trial follows a rigorous protocol structured into five major stages.
At Day 0, the study provides for the inclusion of 400 patients recruited in 7 hospital centers and from 33 private practice physicians (gynecologists, general practitioners, pain specialists) and meeting HAS criteria and presenting symptoms with an intensity of at least 4/10. These participants are then divided fairly (1:1 randomization) into two cohorts: an intervention group that uses the Lyv Endo digital device, and a control group that benefits from standard clinical care. Follow-up is ensured monthly over three months by means of online questionnaires filled in directly by the patients (ePROs). On the 90th day, the primary objective is evaluated by measuring the quality of life of the participants thanks to the standardized EHP-5 score. Beyond the quality of life, the study evaluates the impact of the device on symptom intensity (pain, digestive disorders, mental health via NRS, PHQ-9, GAD-7, CSI), medication consumption, sick leave, medical consultations, as well as the medico-economic impact (cost-utility analysis by EQ-5D-5L scores) and patient compliance and satisfaction regarding the application. Finally, an annex extension phase of three months is implemented to allow all participants to access the application.
Towards a validated digital care in endometriosis
The LYVENDO study constitutes an important step in building clinical evidence regarding digital therapies for endometriosis. If the results confirm the hypothesis, this digital therapy could eventually be integrated into standard care pathways, offering all patients, particularly those with limited access to specialized multidisciplinary care, a validated, accessible, and scalable tool for the self-management of their symptoms.
By participating in this trial, IFEM Endo Bordeaux reaffirms its commitment to producing high-quality evidence on emerging approaches in endometriosis.
Dr. Adrien Crestani, Instructor – IFEM Endo Academy & Surgeon in complex endometriosis care
References
1. Haute Autorité de Santé (HAS). Endométriose : recommandations pour la prise en charge. 2022.
2. Rohloff N, Rothenhöfer M, Götz T, Schäfer SD. Observational pilot study on the influence of an app-based self-management program on the quality of life of women with endometriosis. Arch Gynecol Obstet. 2024. https://doi.org/10.1007/s00404-024-07468-4
